<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739840</url>
  </required_header>
  <id_info>
    <org_study_id>EP0092</org_study_id>
    <secondary_id>2018-002303-33</secondary_id>
    <nct_id>NCT03739840</nct_id>
  </id_info>
  <brief_title>A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy</brief_title>
  <acronym>DUET</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3&#xD;
      selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3&#xD;
      anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset&#xD;
      seizures in subjects with drug-resistant epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on available data, UCB has decided to stop development of padsevonil as adjunctive&#xD;
    treatment of focal-onset seizure&#xD;
  </why_stopped>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Actual">September 28, 2020</completion_date>
  <primary_completion_date type="Actual">September 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Log-transformed Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</measure>
    <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
    <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed seizure frequency from Baseline, with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (Yes or No) and Region (Europe, non-Europe) as categorical factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is as infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>75% Responder Rate From Baseline Over the 12-week Maintenance Period</measure>
    <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
    <description>The 75 % responder rate, where a responder was a participant experiencing a ≥75 % reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% Responder Rate From Baseline Over the 12-week Maintenance Period</measure>
    <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
    <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-week Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</measure>
    <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
    <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) were assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Drug-Resistant Epilepsy</condition>
  <condition>Focal-Onset Seizures</condition>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Padsevonil in different dosages.</description>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be provided matching padsevonil.</description>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of focal epilepsy per 1989 International League Against Epilepsy (ILAE)&#xD;
             criteria at least 3 years before study entry&#xD;
&#xD;
          -  Subject has failed to achieve seizure control with &gt;=4 tolerated and appropriately&#xD;
             chosen prior antiepileptic drugs (AED), including past and ongoing treatment, that&#xD;
             were individually optimized for adequate dose and duration. Prior discontinued AED&#xD;
             treatment would need to be assessed by the Investigator considering the patient&#xD;
             medical records and patient and/or caregiver interview. 'Prior AED' is defined as all&#xD;
             past and ongoing AED treatments with a start date before the Screening Visit (Visit 1)&#xD;
&#xD;
          -  Average of &gt;= 4 spontaneous and observable focal seizures (type IA1 (i.e. focal&#xD;
             aware), IB (i.e. focal impaired awareness), IC (i.e. focal to bilateral tonic-clonic))&#xD;
             per month&#xD;
&#xD;
          -  Current treatment with an individually optimized and stable dose of at least 1 and up&#xD;
             to 3 AEDs for the 8 weeks prior to the Screening Visit with or without additional&#xD;
             Vagus Nerve Stimulation (VNS) or other neurostimulation treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history of or signs of generalized or combined generalized and focal&#xD;
             epilepsy&#xD;
&#xD;
          -  Cluster seizures which are uncountable in the previous 8 weeks before study entry and&#xD;
             during 4 weeks prospective baseline&#xD;
&#xD;
          -  Current treatment with carbamazepine, phenytoin, primidone, phenobarbital&#xD;
&#xD;
          -  Current treatment/ use of (non-AED) prescription, nonprescription, dietary (eg,&#xD;
             grapefruit or passion fruit), or herbal products that are potent inducers or&#xD;
             inhibitors of the CYP3A4 or 2C19 pathway for 2 weeks (or 5 half-lives, whichever is&#xD;
             longer) prior to the Baseline Visit&#xD;
&#xD;
          -  Subjects taking sensitive substrates of CYP2C19 for 2 weeks (or 5 half-lives,&#xD;
             whichever is longer) prior to the Baseline Visit&#xD;
&#xD;
          -  Subject has been taking vigabatrin less than 2 years at study entry&#xD;
&#xD;
          -  Subject has been taking felbamate for less than 12 months&#xD;
&#xD;
          -  Subject taking retigabine for less than 4 years&#xD;
&#xD;
          -  Current treatment with benzodiazepines (i.e. GABA-A-ergic drugs like zolpidem,&#xD;
             zaleplon, or zopiclone, excluding GABA-A-ergic AEDs) &lt;3 times per week for emergencies&#xD;
&#xD;
          -  Subject has a current medical condition that occurred within the last 12 months which,&#xD;
             in the opinion of the investigator, could compromise his/her safety or ability to&#xD;
             participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0092 839</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 881</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 633</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 629</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 845</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 892</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 640</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 641</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 823</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 803</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 637</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 880</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 638</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 630</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 707</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 822</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 818</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 889</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 645</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 644</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 895</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 878</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 876</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 893</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 890</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 884</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 642</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 647</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 882</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 802</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 829</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 639</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 855</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 861</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 850</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 853</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 852</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 109</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 107</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 080</name>
      <address>
        <city>Bihać</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 077</name>
      <address>
        <city>Mostar</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 075</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 082</name>
      <address>
        <city>Tuzla</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 150</name>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 151</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 156</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 154</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 125</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 126</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 127</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 128</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 254</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 258</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 250</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 251</name>
      <address>
        <city>Praha 6</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 016</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 015</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 276</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 277</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 275</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 027</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 312</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 310</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 301</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 365</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 362</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 363</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 350</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 368</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 357</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 376</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 425</name>
      <address>
        <city>Ioánnina</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 426</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 427</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 428</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 403</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 405</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 404</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 035</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 036</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 452</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 526</name>
      <address>
        <city>Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 501</name>
      <address>
        <city>Asaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 521</name>
      <address>
        <city>Bunkyō-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 525</name>
      <address>
        <city>Bunkyō-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 504</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 505</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 513</name>
      <address>
        <city>Hōfu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 507</name>
      <address>
        <city>Itami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 531</name>
      <address>
        <city>Izumi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 539</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 533</name>
      <address>
        <city>Kure</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 514</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 512</name>
      <address>
        <city>Nagakute</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 515</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 508</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 527</name>
      <address>
        <city>Shinagawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 509</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 529</name>
      <address>
        <city>Yonago</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 522</name>
      <address>
        <city>Ōmura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 530</name>
      <address>
        <city>Ōsaka-sayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 775</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 605</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 616</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 603</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 614</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 610</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 620</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 606</name>
      <address>
        <city>Nowa Sól</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 611</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 615</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 619</name>
      <address>
        <city>Zamość</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 618</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 612</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 952</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 950</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 925</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 926</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 927</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 327</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 325</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 004</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 662</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 651</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 652</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 658</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 674</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 657</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 676</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 576</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 575</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 053</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 913</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 915</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 900</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 906</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 909</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 908</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 766</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 750</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0092 764</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Mexico</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Padsevonil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03739840/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03739840/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll participants in March 2019 and concluded in September 2020.</recruitment_details>
      <pre_assignment_details>The study included: a 4-week Baseline Period, a 16-week Treatment Period, a 4-week Taper Period (for participants who discontinued or choose not to enroll in the open-label extension study) and a Safety Follow-up Period. Participants continuing to the OLE study had a 3-week Conversion Period.&#xD;
The Participant Flow refers to the Randomized Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, twice daily (bid) up to Week 19.</description>
        </group>
        <group group_id="P2">
          <title>Padsevonil 100 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19.</description>
        </group>
        <group group_id="P3">
          <title>Padsevonil 200 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19.</description>
        </group>
        <group group_id="P4">
          <title>Padsevonil 400 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period: Wk0-16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Titration and Stabilization</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Program Termination</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Closed Study- Subject Was Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsors Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Promotor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per Sponsor Study Closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Premature Program Termination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Closed By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Early Closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Premature Study Termination By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Premature Closure Of The Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Has Been Cancelled By The Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due To Sponsor Instruction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Was Closed By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Period: Wk16-23</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Conversion Period</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Conversion Period</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Taper and Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Taper and Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in EP0093</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision To Terminate The Study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Closed Study- Subject Was Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision + Subject Refusal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Study Closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Closed By Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Randomized Set (RS) consisted of all participants randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, twice daily (bid) up to Week 19.</description>
        </group>
        <group group_id="B2">
          <title>Padsevonil 100 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19.</description>
        </group>
        <group group_id="B3">
          <title>Padsevonil 200 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19.</description>
        </group>
        <group group_id="B4">
          <title>Padsevonil 400 mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19</description>
        </group>
        <group group_id="B5">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="59"/>
            <count group_id="B5" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="13.6"/>
                    <measurement group_id="B2" value="40.7" spread="13.0"/>
                    <measurement group_id="B3" value="39.5" spread="14.3"/>
                    <measurement group_id="B4" value="39.7" spread="13.6"/>
                    <measurement group_id="B5" value="40.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Log-transformed Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</title>
        <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed seizure frequency from Baseline, with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (Yes or No) and Region (Europe, non-Europe) as categorical factors.</description>
        <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log-transformed Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</title>
          <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed seizure frequency from Baseline, with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (Yes or No) and Region (Europe, non-Europe) as categorical factors.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>log e seizures per 28 days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" lower_limit="-0.6133" upper_limit="-0.2025"/>
                    <measurement group_id="O2" value="-0.35" lower_limit="-0.54906" upper_limit="-0.15705"/>
                    <measurement group_id="O3" value="-0.47" lower_limit="-0.67559" upper_limit="-0.27382"/>
                    <measurement group_id="O4" value="-0.47" lower_limit="-0.67267" upper_limit="-0.27361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.687</p_value>
            <p_value_desc>Adjusted p-values are from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>-5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.1</ci_lower_limit>
            <ci_upper_limit>19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.687</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.7</ci_lower_limit>
            <ci_upper_limit>28.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.687</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.9</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="78.9"/>
                    <measurement group_id="O4" value="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</title>
        <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</title>
          <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</title>
        <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is as infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</title>
          <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: Results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is as infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. A TEAE was defined as any event not present before the initiation of the first dose of study treatment or any unresolved event already present before initiation of the first dose that worsened in intensity following exposure to the treatment.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>75% Responder Rate From Baseline Over the 12-week Maintenance Period</title>
        <description>The 75 % responder rate, where a responder was a participant experiencing a ≥75 % reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
        <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>75% Responder Rate From Baseline Over the 12-week Maintenance Period</title>
          <description>The 75 % responder rate, where a responder was a participant experiencing a ≥75 % reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.803</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>3.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.772</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.989</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50% Responder Rate From Baseline Over the 12-week Maintenance Period</title>
        <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-week Maintenance Period.</description>
        <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>50% Responder Rate From Baseline Over the 12-week Maintenance Period</title>
          <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-week Maintenance Period.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="33.9"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.425</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.625</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), Region (Europe, non-Europe), Baseline SV2A use (Yes, No) and log-transformed Baseline seizure frequency as a continuous covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.125</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</title>
        <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) were assessed.</description>
        <time_frame>From Baseline over the 12 Week Maintenance Period (up to Week 16)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 100 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 200 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 400 mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period</title>
          <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) were assessed.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.34" spread="44.56"/>
                    <measurement group_id="O2" value="11.72" spread="81.52"/>
                    <measurement group_id="O3" value="30.29" spread="39.58"/>
                    <measurement group_id="O4" value="22.41" spread="62.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value are based on the Wilcoxon-Mann-Whitney test. Hodges Lehmann nonparametric effect estimates and corresponding two-sided 95% asymptotic confidence intervals are provided for the effect difference between each PSL dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.737</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>3.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.08</ci_lower_limit>
            <ci_upper_limit>20.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value are based on the Wilcoxon-Mann-Whitney test. Hodges Lehmann nonparametric effect estimates and corresponding two-sided 95% asymptotic confidence intervals are provided for the effect difference between each PSL dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.458</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>6.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.00</ci_lower_limit>
            <ci_upper_limit>21.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value are based on the Wilcoxon-Mann-Whitney test. Hodges Lehmann nonparametric effect estimates and corresponding two-sided 95% asymptotic confidence intervals are provided for the effect difference between each PSL dose and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.341</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>9.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.92</ci_lower_limit>
            <ci_upper_limit>28.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs were collected from Baseline until Safety Follow-Up (up to Week 23)</time_frame>
      <desc>TEAEs counts are for the number of study participants who entered the respective study period regardless of whether or not they completed the previous period. This is the reason for the difference in number of participants in Taper and SFU period in adverse events section and participant flow.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment Period (SS)</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding, bid up to Week 19. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E2">
          <title>Padsevonil 100 mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E3">
          <title>Padsevonil 200 mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E4">
          <title>Padsevonil 400 mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to Week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E5">
          <title>Placebo Conversion Period (SS)</title>
          <description>A 3-Week Conversion Period was required for study participants who chose to enroll in the open-label extension (OLE) study at the end of the 12-Week Maintenance Period. Participants initially randomized to placebo progressively received padsevonil in a blinded way to reach the entry dose of 400 mg/day for the OLE. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E6">
          <title>Padsevonil 100 mg BID Conversion Period (SS)</title>
          <description>A 3-Week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-Week Maintenance Period. The dose for participants initially randomized to padsevonil 100 mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400 mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E7">
          <title>Padsevonil 200 mg BID Conversion Period (SS)</title>
          <description>A 3-Week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-Week Maintenance Period. The dose for participants initially randomized to padsevonil 200 mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400 mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E8">
          <title>Padsevonil 400 mg BID Conversion Period (SS)</title>
          <description>A 3-Week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-Week Maintenance Period. The dose for participants initially randomized to padsevonil 400 mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400 mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E9">
          <title>Placebo Taper and SFU Period (SS)</title>
          <description>A 4-Week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-Week Maintenance Period. Participants initially randomized to placebo group received 5-6 placebo tablets to maintain the blinding and have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E10">
          <title>Padsevonil 100 mg BID Taper and SFU Period (SS)</title>
          <description>A 4-Week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-Week Maintenance Period. Participants initially randomized to padsevonil 100 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
        <group group_id="E11">
          <title>Padsevonil 200 mg BID Taper and SFU Period (SS)</title>
          <description>A 4-Week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-Week Maintenance Period. Participants initially randomized to padsevonil 200 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
        <group group_id="E12">
          <title>Padsevonil 400 mg BID Taper and SFU Period (SS)</title>
          <description>A 4-Week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-Week Maintenance Period. Participants initially randomized to padsevonil 400 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E4" events="23" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E3" events="16" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="12" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1-844-599-2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

